TY - JOUR
T1 - The role of cladribine in acute myeloid leukemia
T2 - an old drug up to new tricks
AU - Molica, Matteo
AU - Breccia, Massimo
AU - Capria, Saveria
AU - Trisolini, Silvia
AU - Foa, Roberto
AU - Jabbour, Elias
AU - Kadia, Tapan Mahendra
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/2/23
Y1 - 2020/2/23
N2 - Despite advances in understanding the pathogenesis of acute myeloid leukemia (AML), the standard therapy remained nearly unchanged for several decades. There have been many efforts to improve the response and survival by either increasing the cytarabine (ARA-C) dose or adding a third agent to the standard chemotherapy regimen. Several studies have evaluated the addition of cladribine (CdA) to standard induction, exploiting its property to potentiate ARA-C uptake. Response rates for combination regimens including CdA in relapsed/refractory (R/R) adults are approximately 50% and approximately 70% in de novo AML. Recently, a low intensity combination of CdA and ARA‐C alternating with decitabine has shown promising results in older patients with AML. In this review, we will discuss the role of CdA in the treatment of AML, summarizing the recent clinical data regarding its incorporation into the induction therapy for adult AML.
AB - Despite advances in understanding the pathogenesis of acute myeloid leukemia (AML), the standard therapy remained nearly unchanged for several decades. There have been many efforts to improve the response and survival by either increasing the cytarabine (ARA-C) dose or adding a third agent to the standard chemotherapy regimen. Several studies have evaluated the addition of cladribine (CdA) to standard induction, exploiting its property to potentiate ARA-C uptake. Response rates for combination regimens including CdA in relapsed/refractory (R/R) adults are approximately 50% and approximately 70% in de novo AML. Recently, a low intensity combination of CdA and ARA‐C alternating with decitabine has shown promising results in older patients with AML. In this review, we will discuss the role of CdA in the treatment of AML, summarizing the recent clinical data regarding its incorporation into the induction therapy for adult AML.
KW - Acute myeloid leukemia
KW - cladribine
KW - combination regimens
UR - http://www.scopus.com/inward/record.url?scp=85075454495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075454495&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1672060
DO - 10.1080/10428194.2019.1672060
M3 - Review article
C2 - 31752577
AN - SCOPUS:85075454495
SN - 1042-8194
VL - 61
SP - 536
EP - 545
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 3
ER -